Groupama Asset Managment Raises Holdings in Hologic, Inc. (NASDAQ:HOLX)

Groupama Asset Managment increased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 63.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 54,214 shares of the medical equipment provider's stock after buying an additional 21,037 shares during the period. Groupama Asset Managment's holdings in Hologic were worth $3,918,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of HOLX. General Partner Inc. bought a new position in shares of Hologic during the 4th quarter worth approximately $26,000. Venturi Wealth Management LLC boosted its stake in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Finally, Smithfield Trust Co boosted its position in shares of Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 400 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Remove Ads

Hologic Stock Performance

Shares of HOLX traded down $0.83 on Friday, reaching $60.86. 6,509,048 shares of the company's stock traded hands, compared to its average volume of 1,842,488. The stock's 50 day simple moving average is $64.30 and its two-hundred day simple moving average is $72.59. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $59.06 and a 52-week high of $84.67. The stock has a market cap of $13.66 billion, a PE ratio of 19.20, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Evercore ISI dropped their price target on Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research note on Thursday, February 6th. Citigroup lowered their target price on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. BNP Paribas raised shares of Hologic to a "strong-buy" rating in a research report on Tuesday, December 10th. Leerink Partnrs downgraded shares of Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Finally, William Blair reiterated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Hologic has an average rating of "Hold" and an average price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.